Photo Credit: Irina Esau

The following is a summary of “Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials,” published in the March 2025 issue of Journal of the American Academy of Dermatology by Gooderham et al. 

Currently, no topical medications are specifically designed and approved for treating moderate to severe chronic hand eczema (CHE).  

Researchers conducted a retrospective study to evaluate the long-term safety and efficacy of delgocitinib cream 20 mg/g for up to 36 weeks (W) in adults with CHE.  

They analyzed data from the phase 3 open-label DELTA 3 trial (NCT04949841), including 801 individuals who completed the 16-W treatment in DELTA 1 and 2. Delgocitinib cream 20 mg/g was applied twice daily as needed for 36W. Treatment continued until Investigator’s Global Assessment for Chronic Hand Eczema (IGA-CHE) was ≤1 for those with IGA-CHE ≥2. The primary endpoint was the number of treatment-emergent adverse events (AEs), while key secondary endpoints included achieving IGA-CHE 0/1 and at least 75% or 90% improvement in Hand Eczema Severity Index (HECSI-75/90) scores.  

The results showed that delgocitinib was well tolerated (n=801; R=231.1; PYO=535.7), with COVID-19 and nasopharyngitis as the most common AEs. In DELTA 3, IGA-CHE 0/1 at baseline (24.6%) increased to 30.0% at W36, while HECSI-75/HECSI-90 response rates improved from 51.8%/31.8% to 58.6%/36.6%. Among those previously treated with cream vehicle, response rates increased from baseline (9.1% for IGA-CHE 0/1 and 23.7%/12.0% for HECSI-75/HECSI-90) to W36 (29.5% and 51.5%/35.7%, respectively).  

Investigators concluded that delgocitinib cream provided well-tolerated and sustained disease control in patients with CHE for up to 52W. 

Source: jaad.org/article/S0190-9622(25)00424-4/fulltext